Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival
Smith, M P
AffiliationManchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester
MetadataShow full item record
AbstractMelanoma is the deadliest form of skin cancer; a primary driver of this high level of morbidity is the propensity of melanoma cells to metastasize. When malignant tumours develop distant metastatic lesions the new local tissue niche is known to impact on the biology of the cancer cells. However, little is known about how different metastatic tissue sites impact on frontline targeted therapies. Intriguingly, melanoma bone lesions have significantly lower response to BRAF or MEK inhibitor therapies. Here, we have investigated how the cellular niche of the bone can support melanoma cells by stimulating growth and survival via paracrine signalling between osteoblasts and cancer cells. Melanoma cells can enhance the differentiation of osteoblasts leading to increased production of secreted ligands, including RANKL. Differentiated osteoblasts in turn can support melanoma cell proliferation and survival via the secretion of RANKL that elevates the levels of the transcription factor MITF, even in the presence of BRAF inhibitor. By blocking RANKL signalling, either via neutralizing antibodies, genetic alterations or the RANKL receptor inhibitor SPD304, the survival advantage provided by osteoblasts could be overcome.
CitationFerguson J, Wilcock DJ, McEntegart S, Badrock AP, Levesque M, Dummer R, et al. Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival. Pigment Cell Melanoma Res. 2019 Jul 19.
JournalPigment Cell & Melanoma Research
- Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation.
- Authors: Kido K, Sumimoto H, Asada S, Okada SM, Yaguchi T, Kawamura N, Miyagishi M, Saida T, Kawakami Y
- Issue date: 2009 Oct
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
- Authors: Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS
- Issue date: 2014 Dec 15
- A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF<sup>high</sup> /AXL<sup>low</sup> melanoma.
- Authors: Smith MP, Rana S, Ferguson J, Rowling EJ, Flaherty KT, Wargo JA, Marais R, Wellbrock C
- Issue date: 2019 Mar
- Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
- Authors: Kundu A, Quirit JG, Khouri MG, Firestone GL
- Issue date: 2017 Jan
- Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
- Authors: Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R
- Issue date: 2008 Jul 16